Towards a chemotherapy-free approach in indolent lymphoma
Mené sur 110 patients atteints d'un lymphome non hodgkinien indolent de stade avancé, cet essai de phase II évalue l'efficacité, du point de vue de la réponse globale, et la toxicité d'un traitement combinant lenalidomide et rituximab
With the introduction of rituximab 20 years ago, treatment of advanced stage indolent B-cell lymphoma has changed greatly since the first evidence that we can improve survival of patients with this incurable disease. However, the remarkable success of rituximab has been largely achieved through the use of rituximab and chemotherapy combinations because rituximab as a single-agent induction therapy is much less effective. Rituximab plus chemotherapy combinations are uniformly accepted as standa ...
The Lancet Oncology , commentaire, 2013